Long-term effects of empagliflozin in patients with chronic kidney disease
<p><strong>Background:</strong> In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to asses...
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Autres auteurs: | |
| Format: | Journal article |
| Langue: | English |
| Publié: |
Massachusetts Medical Society
2024
|
| _version_ | 1826316061707862016 |
|---|---|
| author | Herrington, WG Staplin, N Agrawal, N Wanner, C Green, JB Hauske, SJ Emberson, JR Preiss, D Judge, P Zhu, D Dayanandan, R Arimoto, R Mayne, KJ Ng, SYA Sammons, E Hill, M Stevens, W Wallendszus, K Brenner, S Cheung, AK Liu, Z-H Li, J Hooi, LS Liu, W Kadowaki, T Nangaku, M Levin, A Cherney, DZI Maggioni, AP Pontremoli, R Deo, R Goto, S Rossello, X Tuttle, KR Steubl, D Massey, D Brueckmann, M Landray, MJ Baigent, C Haynes, R |
| author2 | EMPA-KIDNEY Collaborative Group |
| author_facet | EMPA-KIDNEY Collaborative Group Herrington, WG Staplin, N Agrawal, N Wanner, C Green, JB Hauske, SJ Emberson, JR Preiss, D Judge, P Zhu, D Dayanandan, R Arimoto, R Mayne, KJ Ng, SYA Sammons, E Hill, M Stevens, W Wallendszus, K Brenner, S Cheung, AK Liu, Z-H Li, J Hooi, LS Liu, W Kadowaki, T Nangaku, M Levin, A Cherney, DZI Maggioni, AP Pontremoli, R Deo, R Goto, S Rossello, X Tuttle, KR Steubl, D Massey, D Brueckmann, M Landray, MJ Baigent, C Haynes, R |
| author_sort | Herrington, WG |
| collection | OXFORD |
| description | <p><strong>Background:</strong> In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to assess how the effects of empagliflozin would evolve after the discontinuation of the trial drug.</p>
<br>
<p><strong>Methods:</strong> In the active trial, patients with chronic kidney disease were randomly assigned to receive either empagliflozin (10 mg once daily) or matching placebo and were followed for a median of 2 years. All the patients had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area or an eGFR of at least 45 but less than 90 ml per minute per 1.73 m2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Subsequently, surviving patients who consented were observed for 2 additional years. No trial empagliflozin or placebo was administered during the post-trial period, but local practitioners could prescribe open-label SGLT2 inhibitors, including open-label empagliflozin. The primary composite outcome was kidney disease progression or cardiovascular death as assessed from the start of the active-trial period to the end of the post-trial period.</p>
<br>
<p><strong>Results:</strong> Of the 6609 patients who had undergone randomization in the active trial, 4891 (74%) were enrolled in the post-trial period. During this period, the use of open-label SGLT2 inhibitors was similar in the two groups (43% in the empagliflozin group and 40% in the placebo group). During the combined active- and post-trial periods, a primary-outcome event occurred in 865 of 3304 patients (26.2%) in the empagliflozin group and in 1001 of 3305 patients (30.3%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.72 to 0.87). During the post-trial period only, the hazard ratio for a primary-outcome event was 0.87 (95% CI, 0.76 to 0.99). During the combined periods, the risk of kidney disease progression was 23.5% in the empagliflozin group and 27.1% in the placebo group; the risk of the composite of death or end-stage kidney disease was 16.9% and 19.6%, respectively; and the risk of cardiovascular death was 3.8% and 4.9%, respectively. There was no effect of empagliflozin on death from noncardiovascular causes (5.3% in both groups).</p>
<br>
<p><strong>Conclusions:</strong> In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, 2017-002971-24.)</p> |
| first_indexed | 2024-12-09T03:37:17Z |
| format | Journal article |
| id | oxford-uuid:50b57514-e09a-4154-a1c3-d56c21a7c32a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:37:17Z |
| publishDate | 2024 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:50b57514-e09a-4154-a1c3-d56c21a7c32a2024-12-03T11:45:58ZLong-term effects of empagliflozin in patients with chronic kidney diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:50b57514-e09a-4154-a1c3-d56c21a7c32aEnglishSymplectic ElementsMassachusetts Medical Society2024Herrington, WGStaplin, NAgrawal, NWanner, CGreen, JBHauske, SJEmberson, JRPreiss, DJudge, PZhu, DDayanandan, RArimoto, RMayne, KJNg, SYASammons, EHill, MStevens, WWallendszus, KBrenner, SCheung, AKLiu, Z-HLi, JHooi, LSLiu, WKadowaki, TNangaku, MLevin, ACherney, DZIMaggioni, APPontremoli, RDeo, RGoto, SRossello, XTuttle, KRSteubl, DMassey, DBrueckmann, MLandray, MJBaigent, CHaynes, REMPA-KIDNEY Collaborative Group<p><strong>Background:</strong> In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to assess how the effects of empagliflozin would evolve after the discontinuation of the trial drug.</p> <br> <p><strong>Methods:</strong> In the active trial, patients with chronic kidney disease were randomly assigned to receive either empagliflozin (10 mg once daily) or matching placebo and were followed for a median of 2 years. All the patients had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area or an eGFR of at least 45 but less than 90 ml per minute per 1.73 m2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Subsequently, surviving patients who consented were observed for 2 additional years. No trial empagliflozin or placebo was administered during the post-trial period, but local practitioners could prescribe open-label SGLT2 inhibitors, including open-label empagliflozin. The primary composite outcome was kidney disease progression or cardiovascular death as assessed from the start of the active-trial period to the end of the post-trial period.</p> <br> <p><strong>Results:</strong> Of the 6609 patients who had undergone randomization in the active trial, 4891 (74%) were enrolled in the post-trial period. During this period, the use of open-label SGLT2 inhibitors was similar in the two groups (43% in the empagliflozin group and 40% in the placebo group). During the combined active- and post-trial periods, a primary-outcome event occurred in 865 of 3304 patients (26.2%) in the empagliflozin group and in 1001 of 3305 patients (30.3%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.72 to 0.87). During the post-trial period only, the hazard ratio for a primary-outcome event was 0.87 (95% CI, 0.76 to 0.99). During the combined periods, the risk of kidney disease progression was 23.5% in the empagliflozin group and 27.1% in the placebo group; the risk of the composite of death or end-stage kidney disease was 16.9% and 19.6%, respectively; and the risk of cardiovascular death was 3.8% and 4.9%, respectively. There was no effect of empagliflozin on death from noncardiovascular causes (5.3% in both groups).</p> <br> <p><strong>Conclusions:</strong> In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, 2017-002971-24.)</p> |
| spellingShingle | Herrington, WG Staplin, N Agrawal, N Wanner, C Green, JB Hauske, SJ Emberson, JR Preiss, D Judge, P Zhu, D Dayanandan, R Arimoto, R Mayne, KJ Ng, SYA Sammons, E Hill, M Stevens, W Wallendszus, K Brenner, S Cheung, AK Liu, Z-H Li, J Hooi, LS Liu, W Kadowaki, T Nangaku, M Levin, A Cherney, DZI Maggioni, AP Pontremoli, R Deo, R Goto, S Rossello, X Tuttle, KR Steubl, D Massey, D Brueckmann, M Landray, MJ Baigent, C Haynes, R Long-term effects of empagliflozin in patients with chronic kidney disease |
| title | Long-term effects of empagliflozin in patients with chronic kidney disease |
| title_full | Long-term effects of empagliflozin in patients with chronic kidney disease |
| title_fullStr | Long-term effects of empagliflozin in patients with chronic kidney disease |
| title_full_unstemmed | Long-term effects of empagliflozin in patients with chronic kidney disease |
| title_short | Long-term effects of empagliflozin in patients with chronic kidney disease |
| title_sort | long term effects of empagliflozin in patients with chronic kidney disease |
| work_keys_str_mv | AT herringtonwg longtermeffectsofempagliflozininpatientswithchronickidneydisease AT staplinn longtermeffectsofempagliflozininpatientswithchronickidneydisease AT agrawaln longtermeffectsofempagliflozininpatientswithchronickidneydisease AT wannerc longtermeffectsofempagliflozininpatientswithchronickidneydisease AT greenjb longtermeffectsofempagliflozininpatientswithchronickidneydisease AT hauskesj longtermeffectsofempagliflozininpatientswithchronickidneydisease AT embersonjr longtermeffectsofempagliflozininpatientswithchronickidneydisease AT preissd longtermeffectsofempagliflozininpatientswithchronickidneydisease AT judgep longtermeffectsofempagliflozininpatientswithchronickidneydisease AT zhud longtermeffectsofempagliflozininpatientswithchronickidneydisease AT dayanandanr longtermeffectsofempagliflozininpatientswithchronickidneydisease AT arimotor longtermeffectsofempagliflozininpatientswithchronickidneydisease AT maynekj longtermeffectsofempagliflozininpatientswithchronickidneydisease AT ngsya longtermeffectsofempagliflozininpatientswithchronickidneydisease AT sammonse longtermeffectsofempagliflozininpatientswithchronickidneydisease AT hillm longtermeffectsofempagliflozininpatientswithchronickidneydisease AT stevensw longtermeffectsofempagliflozininpatientswithchronickidneydisease AT wallendszusk longtermeffectsofempagliflozininpatientswithchronickidneydisease AT brenners longtermeffectsofempagliflozininpatientswithchronickidneydisease AT cheungak longtermeffectsofempagliflozininpatientswithchronickidneydisease AT liuzh longtermeffectsofempagliflozininpatientswithchronickidneydisease AT lij longtermeffectsofempagliflozininpatientswithchronickidneydisease AT hooils longtermeffectsofempagliflozininpatientswithchronickidneydisease AT liuw longtermeffectsofempagliflozininpatientswithchronickidneydisease AT kadowakit longtermeffectsofempagliflozininpatientswithchronickidneydisease AT nangakum longtermeffectsofempagliflozininpatientswithchronickidneydisease AT levina longtermeffectsofempagliflozininpatientswithchronickidneydisease AT cherneydzi longtermeffectsofempagliflozininpatientswithchronickidneydisease AT maggioniap longtermeffectsofempagliflozininpatientswithchronickidneydisease AT pontremolir longtermeffectsofempagliflozininpatientswithchronickidneydisease AT deor longtermeffectsofempagliflozininpatientswithchronickidneydisease AT gotos longtermeffectsofempagliflozininpatientswithchronickidneydisease AT rossellox longtermeffectsofempagliflozininpatientswithchronickidneydisease AT tuttlekr longtermeffectsofempagliflozininpatientswithchronickidneydisease AT steubld longtermeffectsofempagliflozininpatientswithchronickidneydisease AT masseyd longtermeffectsofempagliflozininpatientswithchronickidneydisease AT brueckmannm longtermeffectsofempagliflozininpatientswithchronickidneydisease AT landraymj longtermeffectsofempagliflozininpatientswithchronickidneydisease AT baigentc longtermeffectsofempagliflozininpatientswithchronickidneydisease AT haynesr longtermeffectsofempagliflozininpatientswithchronickidneydisease |